The ‘Sanming Model’: Bad Omen Or Hope For Pharma In China?

Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.